Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Immunomodulatory effects of soluble CD5 on experimental tumor models.

Simões IT, Aranda F, Carreras E, Andrés MV, Casadó-Llombart S, Martinez VG, Lozano F.

Oncotarget. 2017 Nov 20;8(64):108156-108169. doi: 10.18632/oncotarget.22564. eCollection 2017 Dec 8.

2.

A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease.

Korenfeld D, Gorvel L, Munk A, Man J, Schaffer A, Tung T, Mann C, Klechevsky E.

JCI Insight. 2017 Sep 21;2(18). pii: 96101. doi: 10.1172/jci.insight.96101. [Epub ahead of print]

3.

T Cell's Sense of Self: a Role of Self-Recognition in Shaping Functional Competence of Naïve T Cells.

Kim HO, Cho JH.

Immune Netw. 2017 Aug;17(4):201-213. doi: 10.4110/in.2017.17.4.201. Epub 2017 Aug 23. Review.

4.

Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses.

Carrasco E, Escoda-Ferran C, Climent N, Miró-Julià C, Simões IT, Martínez-Florensa M, Sarukhan A, Carreras E, Lozano F.

Front Immunol. 2017 Jun 30;8:769. doi: 10.3389/fimmu.2017.00769. eCollection 2017.

5.

CD6 Receptor Regulates Intestinal Ischemia/Reperfusion-induced Injury by Modulating Natural IgM-producing B1a Cell Self-renewal.

Enyindah-Asonye G, Li Y, Xin W, Singer NG, Gupta N, Fung J, Lin F.

J Biol Chem. 2017 Jan 13;292(2):661-671. doi: 10.1074/jbc.M116.749804. Epub 2016 Dec 1.

6.

CD6 modulates thymocyte selection and peripheral T cell homeostasis.

Orta-Mascaró M, Consuegra-Fernández M, Carreras E, Roncagalli R, Carreras-Sureda A, Alvarez P, Girard L, Simões I, Martínez-Florensa M, Aranda F, Merino R, Martínez VG, Vicente R, Merino J, Sarukhan A, Malissen M, Malissen B, Lozano F.

J Exp Med. 2016 Jul 25;213(8):1387-97. doi: 10.1084/jem.20151785. Epub 2016 Jul 4.

7.

Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.

Menon R, David BG.

Clin Cosmet Investig Dermatol. 2015 Apr 17;8:215-22. doi: 10.2147/CCID.S47784. eCollection 2015. Review. Erratum in: Clin Cosmet Investig Dermatol. 2015;8:295.

8.

Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses.

Fenutría R, Martinez VG, Simões I, Postigo J, Gil V, Martínez-Florensa M, Sintes J, Naves R, Cashman KS, Alberola-Ila J, Ramos-Casals M, Soldevila G, Raman C, Merino J, Merino R, Engel P, Lozano F.

PLoS One. 2014 Jan 15;9(1):e84895. doi: 10.1371/journal.pone.0084895. eCollection 2014.

9.

T-cell modulatory properties of CD5 and its role in antitumor immune responses.

Tabbekh M, Mokrani-Hammani M, Bismuth G, Mami-Chouaib F.

Oncoimmunology. 2013 Jan 1;2(1):e22841.

10.

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Alonso-Ramirez R, Loisel S, Buors C, Pers JO, Montero E, Youinou P, Renaudineau Y.

Arthritis. 2010;2010:130646. doi: 10.1155/2010/130646. Epub 2011 Feb 10.

11.

CD6 attenuates early and late signaling events, setting thresholds for T-cell activation.

Oliveira MI, Gonçalves CM, Pinto M, Fabre S, Santos AM, Lee SF, Castro MA, Nunes RJ, Barbosa RR, Parnes JR, Yu C, Davis SJ, Moreira A, Bismuth G, Carmo AM.

Eur J Immunol. 2012 Jan;42(1):195-205. doi: 10.1002/eji.201040528. Epub 2011 Nov 28.

12.

A conserved enhancer element differentially regulates developmental expression of CD5 in B and T cells.

Berland R, Fiering S, Wortis HH.

J Immunol. 2010 Dec 15;185(12):7537-43. doi: 10.4049/jimmunol.1002173. Epub 2010 Nov 12.

13.

CD5 sweetens lymphocyte responses.

Lenz LL.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1303-4. doi: 10.1073/pnas.0812579106. Epub 2009 Jan 27. No abstract available.

14.

The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome.

Vera J, Fenutría R, Cañadas O, Figueras M, Mota R, Sarrias MR, Williams DL, Casals C, Yelamos J, Lozano F.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1506-11. doi: 10.1073/pnas.0805846106. Epub 2009 Jan 13.

15.

CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock.

Sarrias MR, Farnós M, Mota R, Sánchez-Barbero F, Ibáñez A, Gimferrer I, Vera J, Fenutría R, Casals C, Yélamos J, Lozano F.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11724-9. Epub 2007 Jun 29.

16.

CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76.

Hassan NJ, Simmonds SJ, Clarkson NG, Hanrahan S, Puklavec MJ, Bomb M, Barclay AN, Brown MH.

Mol Cell Biol. 2006 Sep;26(17):6727-38. Erratum in: Mol Cell Biol. 2009 Jun;29(12):3452.

17.

Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets.

Jin P, Wang E, Provenzano M, Deola S, Selleri S, Ren J, Voiculescu S, Stroncek D, Panelli MC, Marincola FM.

J Transl Med. 2006 Jun 28;4:26.

18.

Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential.

Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, Masch R, Lockwood CJ, Schachter AD, Park PJ, Strominger JL.

J Exp Med. 2003 Oct 20;198(8):1201-12.

Supplemental Content

Support Center